TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2019

Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma.

Owen A O'Connor et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.